EGFR-Mutated NSCLC: Subcutaneous Therapies and Future Directions

In this final segment, Dr. Sands asks Dr. Cooper to discuss how subcutaneous administration of targeted therapies may influence clinical practice in EGFR-mutated non-small cell lung cancer. Dr. Cooper highlights that subcutaneous delivery has the potential to reduce administration time and improve patient convenience compared with intravenous therapy, which may positively impact clinic workflow and patient experience. However, she notes that overall treatment burden extends beyond route of administration and includes ongoing toxicity management and monitoring. The discussion emphasizes that patient preferences and quality-of-life considerations remain central when evaluating these approaches. The program concludes with closing reflections from Dr. Wakelee, Dr. Cooper, and Dr. Sands, who highlight ongoing unmet needs, including optimizing sequencing strategies, improving management of resistance mechanisms, and refining the role of emerging therapies. Overall, this segment underscores the importance of continued innovation and personalized care in EGFR-mutated NSCLC.